Literature DB >> 10371277

Serum MMP-3 in rheumatoid arthritis: correlation with systemic inflammation but not with erosive status.

A So1, A M Chamot, V Péclat, J C Gerster.   

Abstract

OBJECTIVE: Metalloproteinases (MMP) play an important role in the remodelling of the extracellular matrix. However, evidence that they are responsible for tissue damage in pathological situations remains circumstantial. Stromelysin (MMP-3) production is increased in rheumatoid arthritis (RA), and has been proposed as a marker of joint damage. The relevance of serum levels of MMP-3 to erosions in RA was studied.
METHODS: Fifty-three patients with active RA of > 5 yr duration and with available X-rays were stratified according to disease duration. Hand X-rays were scored for erosions. Patients were then classified into upper and lower quartiles. Serum MMP-3 levels were compared between these two groups.
RESULTS: No significant differences in serum MMP-3 were seen between high and low eroders. A statistically significant correlation was observed between sMMP-3 and erthyrocyte sedimentation rate and C-reactive protein.
CONCLUSIONS: Serum MMP-3 is not an independent marker of joint damage, but is correlated with systemic inflammation. Its precise role in joint damage in RA remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10371277     DOI: 10.1093/rheumatology/38.5.407

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  8 in total

1.  Matrix Metalloproteinases-3 Baseline Serum Levels in Early Rheumatoid Arthritis Patients without Initial Radiographic Changes: A Two-Year Ultrasonographic Study.

Authors:  Slavica Z Prodanovic; Goran Radunovic; Dragan Babic; Biljana Ristic; Mirjana Sefik-Bukilica; Maja Zlatanovic; Katarina Simic-Pasalic; Srdjan Seric; Nada Vujasinovic-Stupar; Janko Samardzic; Nemanja Damjanov
Journal:  Med Princ Pract       Date:  2018-05-24       Impact factor: 1.927

2.  Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases-1, -2, and -3.

Authors:  B Stix; T Kähne; K Sletten; J Raynes; A Roessner; C Röcken
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

3.  Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation.

Authors:  A A den Broeder; L A B Joosten; T Saxne; D Heinegård; H Fenner; A M M Miltenburg; W L H Frasa; L J van Tits; W A Buurman; P L C M van Riel; L B A van de Putte; P Barrera
Journal:  Ann Rheum Dis       Date:  2002-04       Impact factor: 19.103

4.  A multiparameter approach to monitor disease activity in collagen-induced arthritis.

Authors:  Sylvie Seeuws; Peggy Jacques; Jens Van Praet; Michael Drennan; Julie Coudenys; Tine Decruy; Ellen Deschepper; Lien Lepescheux; Philippe Pujuguet; Line Oste; Nick Vandeghinste; Reginald Brys; Gust Verbruggen; Dirk Elewaut
Journal:  Arthritis Res Ther       Date:  2010-08-23       Impact factor: 5.156

5.  An estrogen-sensitive fibroblast population drives abdominal muscle fibrosis in an inguinal hernia mouse model.

Authors:  Tanvi Potluri; Matthew J Taylor; Jonah J Stulberg; Richard L Lieber; Hong Zhao; Serdar E Bulun
Journal:  JCI Insight       Date:  2022-04-19

Review 6.  Role of fetuin A in the diagnosis and treatment of joint arthritis.

Authors:  Eleni Pappa; Despina S Perrea; Spiridon Pneumaticos; Vasileios S Nikolaou
Journal:  World J Orthop       Date:  2017-06-18

7.  Serum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis.

Authors:  Mahmood M T M Ally; Bridget Hodkinson; Pieter W A Meyer; Eustasius Musenge; Mohammed Tikly; Ronald Anderson
Journal:  Mediators Inflamm       Date:  2013-04-07       Impact factor: 4.711

8.  Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis: comparison with traditional markers.

Authors:  Aşkin Ateş; Nuran Türkçapar; Umit Olmez; Olcay Tiryaki; Nurşen Düzgün; Emre Uğuz; Murat Duman
Journal:  Rheumatol Int       Date:  2007-04-11       Impact factor: 3.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.